Portal de Periódicos da CAPES

Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

2013; National Academy of Sciences; Volume: 110; Issue: 47 Linguagem: Inglês

10.1073/pnas.1317918110

1091-6490

Tammie L.S. Benzinger, Tyler Blazey, Clifford R. Jack, Robert A. Koeppe, Yi Su, Chengjie Xiong, Marcus E. Raichle, Abraham Z. Snyder, Beau M. Ances, Randall J. Bateman, Nigel J. Cairns, Anne M. Fagan, Alison Goate, Daniel S. Marcus, Paul Aisen, Jon Christensen, Lindsay Ercole, Russ C. Hornbeck, Angela Farrar, Patricia Aldea, Mateusz S. Jasielec, Christopher J. Owen, Xianyun Xie, Richard Mayeux, Adam M. Brickman, Eric McDade, William E. Klunk, Chester A. Mathis, John M. Ringman, Paul M. Thompson, Bernardino Ghetti, Andrew J. Saykin, Reisa A. Sperling, Keith A. Johnson, Stephen Salloway, Stephen Correia, Peter R. Schofield, Colin L. Masters, Christopher C. Rowe, Victor L. Villemagne, Ralph N. Martins, Sébastien Ourselin, Martin N. Rossor, Nick C. Fox, David M. Cash, Michael W. Weiner, David M. Holtzman, Virginia Buckles, Krista L. Moulder, John C. Morris,

Advanced Neuroimaging Techniques and Applications

Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.